Factor V G1691A is associated with an increased risk of retinal vein occlusion: a meta-analysis

SummarySeveral small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62–3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19–2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.

Download Full-text

Prevalence of Factor V Leiden in Young Adults with Retinal Vein Occlusion

Thrombosis and Haemostasis ◽

10.1055/s-0038-1655933 ◽

1997 ◽

Vol 77 (01) ◽

pp. 214-216 ◽

Cited By ~ 23

Author(s):

Tuuli Linna ◽

Antti Ylikorkala ◽

Kimmo E Kontula ◽

Päivi Puska ◽

Timo Tervo

Keyword(s):

Young Adults ◽

Retinal Vein Occlusion ◽

Factor V Leiden ◽

Factor V ◽

Vein Occlusion

Download Full-text

Faculty Opinions recommendation of Retinal vein occlusion and risk of cerebrovascular disease and myocardial infarction: A meta-analysis of cohort studies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726179074.793544723 ◽

2018 ◽

Author(s):

David Boyer

Keyword(s):

Myocardial Infarction ◽

Cohort Studies ◽

Cerebrovascular Disease ◽

Retinal Vein Occlusion ◽

Meta Analysis ◽

Vein Occlusion

Download Full-text

Prevalence of Retinal Vein Occlusion in Europe: A Systematic Review and Meta-Analysis

Ophthalmologica ◽

10.1159/000494224 ◽

2018 ◽

Vol 241 (4) ◽

pp. 183-189 ◽

Cited By ~ 2

Author(s):

Jeany Q. Li ◽

Jan Henrik Terheyden ◽

Thomas Welchowski ◽

Matthias Schmid ◽

Julia Letow ◽

...

Keyword(s):

Systematic Review ◽

Retinal Vein Occlusion ◽

Meta Analysis ◽

Vein Occlusion

Download Full-text

Vitamin B12 and Folate as Risk Factors for Retinal Vein Occlusion: A Meta-Analysis

Klinische Monatsblätter für Augenheilkunde ◽

10.1055/a-1473-5897 ◽

2021 ◽

Author(s):

Dimitrios Kazantzis ◽

Panagiotis Theodossiadis ◽

Christos Kroupis ◽

George Theodossiadis ◽

Irini Chatziralli

Keyword(s):

Vitamin B12 ◽

Retinal Vein Occlusion ◽

Meta Analysis ◽

Serum Vitamin ◽

Mean Difference ◽

Serum Folate ◽

Case Control Studies ◽

Vein Occlusion ◽

Pubmed Database ◽

Significant Difference

Abstract Purpose To evaluate the association between serum vitamin B12/folate and retinal vein occlusion (RVO). Methods A comprehensive search of the PubMed database was performed, which identified 271 abstracts to be screened. Ten studies met our inclusion criteria and a meta-analysis of these comparative case-control studies was performed on the mean ± standard deviation serum vitamin B12 and folate levels, without language restrictions. Nine studies with 720 patients with RVO and 613 controls were included in the meta-analysis for vitamin B12, and 10 studies with 784 patients with RVO and 677 controls in the meta-analysis for folate. Results There was no statistically significant difference between patients with RVO and controls in serum vitamin B12 levels (mean difference: − 40.25 pg/mL, p = 0.28), either central RVO (mean difference: − 18.24 pg/mL, p = 0.71) or branch RVO (mean difference: − 23.56 pg/mL, p = 0.48). On the contrary, the plasma folate level was significantly lower in RVO patients than in controls (mean difference: − 1.34 ng/mL, p = 0.001), as well as in patients with CRVO compared to controls (mean difference: − 1.48 ng/mL, p = 0.006), but not in BRVO patients (mean difference: − 0.72 ng/mL, p = 0.11). Conclusions RVO is associated with low serum folate levels, but not with serum vitamin B12 levels.

Download Full-text

Increased risk of cancer in patients with retinal vein occlusion: a 12-year nationwide cohort study

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2020-316947 ◽

2020 ◽

pp. bjophthalmol-2020-316947

Author(s):

Min Seok Kim ◽

Joon Hee Cho ◽

Seong Jun Byun ◽

Chang-Mo Oh ◽

Kyu Hyung Park ◽

...

Keyword(s):

Retinal Vein Occlusion ◽

Cox Regression ◽

Subsequent Development ◽

Population Based ◽

Control Group ◽

Time Varying ◽

Vein Occlusion ◽

Increased Risk ◽

Risk Of Cancer ◽

Subsequent Cancer

AimsTo investigate the association between incident retinal vein occlusion (RVO) and the subsequent development of cancer.MethodsIn this nationwide population-based retrospective study using 2002–2013 National Health Insurance Service database which covers the entire South Korean population, 186 701 incident RVO patients and their 1:1 propensity-score matched controls were included. We defined the fixed cohort from January 1st, 2004 to December 31st, 2013; the cohort included patients who suffered incident RVO after entering the cohort and their matched controls, and excluded patients having any cancer history before entering the cohort. The association of RVO and cancer was assessed by time-varying covariate Cox regression models; Model 1 included RVO as a time-varying covariate, Model 2 included Model 1 plus demographic information and Model 3 included Model 2 and comorbidities.ResultsRVO was associated with an increased risk of subsequent cancer (HR=1.29; 95% CI, 1.26–1.31 in Model 1), which was consistent in Models 2 and 3. The incidence rate of overall cancer during the study period was 25.55 (95% CI, 25.19–25.91) per 1000 person-years in the RVO group and 18.62 (95% CI, 18.46–18.79) per 1000 person-years in the control group. In the subgroup analysis, haematological malignancies showed the highest association with RVO (HR=1.65; 95% CI, 1.49–1.83).ConclusionPatients with RVO have an increased risk of subsequent cancer development even after adjusting for demographic factors and comorbidities. Further study is warranted to elucidate these associations to provide proper recommendations for RVO patients regarding the cancer screening.

Download Full-text

Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis

Clinical and Experimental Ophthalmology ◽

10.1111/ceo.12286 ◽

2014 ◽

Vol 42 (7) ◽

pp. 637-649 ◽

Cited By ~ 3

Author(s):

Shuangwen Zhou ◽

Jianping Gao ◽

Xun Xu

Keyword(s):

Growth Factors ◽

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Macular Oedema ◽

Meta Analysis ◽

Vein Occlusion ◽

Endothelial Growth Factors ◽

Central Retinal Vein

Download Full-text

Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review

BMJ Open ◽

10.1136/bmjopen-2019-032128 ◽

2020 ◽

Vol 10 (6) ◽

pp. e032128

Author(s):

Shuai Ming ◽

Kunpeng Xie ◽

Mingzhu Yang ◽

Huijuan He ◽

Ya Li ◽

...

Keyword(s):

Systematic Review ◽

Retinal Vein Occlusion ◽

Real World ◽

Meta Analysis ◽

Real Life ◽

Cochrane Library ◽

Efficacy And Safety ◽

Vein Occlusion ◽

Anti Vegf ◽

Intravitreal Dexamethasone

ObjectiveTo compare the efficacy and safety of intravitreal dexamethasone (DEX) implant and anti-vascular endothelial growth factor (anti-VEGF) agents in the treatment of macular oedema secondary to retinal vein occlusion (RVO).DesignSystematic review and meta-analysis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE).Data sourcesPubMed, Cochrane Library and ClinicalTrials.gov registry were searched from inception to 10 December 2019, without language restrictions.Eligibility criteriaRandomised controlled trials (RCTs) and real-world observation studies comparing the efficacy of DEX implant and anti-VEGF agents for the treatment of patients with RVO, naïve or almost naïve to both arms, were included.Data extraction and synthesisTwo reviewers independently extracted data for mean changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) and product safety. Review Manager V.5.3 and GRADE were used to synthesise the data and validate the evidence, respectively.ResultsFour RCTs and 12 real-world studies were included. An average lower letter gain in BCVA was determined for the DEX implant (mean difference (MD) = −6.59; 95% CI −8.87 to −4.22 letters) administered at a retreatment interval of 5–6 months. Results were similar (MD6 months=−12.68; 95% CI −21.98 to −3.37 letters; MD12 months=−9.69; 95% CI −12.01 to −7.37 letters) at 6 and 12 months. The DEX implant resulted in comparable or marginally less CST reduction at months 6 and 12 but introduced relatively higher risks of elevated intraocular pressure (RR=3.89; 95% CI 2.16 to 7.03) and cataract induction (RR=5.22; 95% CI 1.67 to 16.29). Most real-life studies reported an insignificant numerical gain in letters for anti-VEGF drugs relative to that for DEX implant. However, the latter achieved comparable efficacy with a 4-month dosage interval.ConclusionCompared with anti-VEGF agents, DEX implant required fewer injections but had inferior functional efficacy and safety. Real-life trials supplemented the efficacy data for DEX implant.

Download Full-text